Genome-environment interactions and prospective technology assessment: Evolution from pharmacogenomics to nutrigenomics and ecogenomics

OMICS A Journal of Integrative Biology

Volumn 13, Issue 1, 2009, Pages 1-6

  Ozdemir, Vural ^a   Motulsky, Arno G ^b   Kolker, Eugene ^b,c,d   Godard, Béatrice ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; MEDICAL ETHICS; MEDICAL RESEARCH; METAGENOMICS; NONHUMAN; NUTRIGENOMICS; PATENT; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY;

DIET; ENVIRONMENT; GENOME, HUMAN; HUMANS; NUTRIGENOMICS; PHARMACOGENETICS; PHENOTYPE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 64949139020     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2009.0013     Document Type: Short Survey

References (47)

1. American Society of Human Genetics. (2007). ASHG statement on direct-to-consumer genetic testing in the United States. Am J Hum Genet 81, 635-637.
2. Blankeslee, A.F., and Salmon, M.R. (1931). Odor and taste-blindness. Eugen News 16, 105-110.
3. Breen, F.M., Plomin, R., and Wardle, J. (2006). Heritability of food preferences in young children. Physiol Behav 88, 443-447.
4. Brewer, G.J. (1971). Annotation: human ecology, an expanding role for the human geneticist. Am J Hum Genet 23, 92-94.
5. Carpenter, K.J. (2003). A short history of nutritional science: part 1 (1785-1885). J Nutr 133, 638-645.
6. Caulfield, T. (2009). Nutrigenomics patents and commercialization: old wine in a new bottle? OMICS 13, 63-67.
7. Compagni, A., Bartoli, S., Buehrlen, B., Fattore, G., Ibarreta, D., and de Mesa, E.G. (2008). Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 24, 294-302.
8. Costa, L., and Eaton, D.L. (2006). Gene-environment interactions: fundamentals of ecogenetics. (John Wiley and Sons: Hoboken, NJ).
9. de Leon, J. (2009). The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 59, 81-89.
10. de Leon, J., Arranz, M.J., and Ruaño, G. (2008). Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 28, 599-617.
11. Fox, A.L. (1932). The relationship between chemical constitution and taste. Proc Natl Acad Sci USA 18, 115-120.
12. Garcia-Bailo, B., Toguri, C., Eny, K.M., and El-Sohemy, A. (2009). Genetic variation in taste and its influence on food selection. OMICS 13, 69-80.
13. Godard, B., and Ozdemir, V. (2008). Nutrigenomics and personalized diet: from molecule to intervention and nutri-ethics. OMICS 12, 227-228.
14. Gurwitz, D., and Motulsky, A.G. (2007). Drug reactions, enzymes, and biochemical genetics: 50 years later. Pharmacoge-nomics 8, 1479-1484.
15. Gurwitz, D., Zika, E., Hopkins, M.M., Gaisser, S., and Ibarreta D. (2009). Pharmacogenetics in Europe: Barriers and opportunities. Public Health Genomics 12, 134-141. (DOI: 10.1159/ 000189625).
16. Guston, D.H. (2008). Innovation policy: not just a jumbo shrimp. Nature 454, 940-941.
17. Guston, D.H., Sarewitz, D., and Miller, C. (2009). Scientists not immune to partisanship. Science 323, 582.
18. Harding, S. (1998). Is science multicultural? Postcolonialisms, feminisms, and epistemologies. (Indiana University Press: Bloomington, IN) pp. 1-242.
19. Havel, V. (1999). Address by Vaclav Havel President of the Czech Republic in acceptance of "Open Society" Prize by the Central European University. Budapest, June 24. Available online at: http://old.hrad.cz/ president/Havel/speeches/1999/ 2406-uk.html. Accessed February 11, 2009.
20. Holtzman, N.A. (1988). Genetic variation in nutritional requirements and susceptibility to disease: policy implications. Am J Clin Nutr 48, 1510-1516.
21. Human Genetics Commission. (2003). Genes Direct: Ensuring the Effective Oversight of Genetic Tests Supplied Directly to the Public. (Human Genetics Commission, Department of Health, London).
22. Ibarreta, D. (2008). Interview. Personal Med 5, 331-334.
23. Institute of Medicine. (2007). Nutrigenomics and Beyond: Informing the Future. (National Academies Press, Washington, DC).
24. Kalow, W. (1962). Pharmacogenetics. Heredity and the Response to Drugs. (W.B. Saunders Co., Philadelphia).
25. Kalow, W. (1992). Pharmacoanthropology and the genetics of drug metabolism. In: Pharmacogenetics of Drug Metabolism. W. Kalow, ed. (Pergamon Press Inc: New York), pp. 865- 877.
26. Khymenets, O., Fito, M., Covas, M.I., Farré, M., Pujadas, M.A., Muñoz, D., et al. (2009). Mononuclear cell transcriptome response after sustained virgin olive oil consumption in humans: an exploratory nutrigenomics study. OMICS 13, 7-19.
27. Kolker, E., Higdon, R., and Hogan, J.M. (2006). Protein identification and expression analysis using mass spectrometry. Trends Microbiol 14, 229-235.
28. Lien, L.F., Haqq, A.M., Arlotto, M., Slentz, C.A., Muehlbauer, M.J., McMahon, R.L., et al. (2009). The STEDMAN Project: biophysical, biochemical and metabolic effects of a behavioral weight loss intervention during weight loss, maintenance and regain. OMICS 13, 21-35.
29. Llerena, A., Dorado, P., and Peñas-Lledó, E.M. (2009). Pharma-cogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10, 17-28.
30. Master, Z., and Ozdemir, V. (2008). Selling translational research-is science a value-neutral autonomous enterprise? Am J Bioeth 8, 52-54.
31. Morin, K. (2009). Knowledge and attitudes of Canadian consumers and health care professionals regarding nutritional ge-nomics. OMICS 13, 37-41.
32. Motulsky, A.G. (1957). Drug reactions, enzymes and biochemical genetics. JAMA 165, 835-837.
33. Motulsky, A.G. (2002). From pharmacogenetics and ecogenetics to pharmacogenomics. Med Secoli 14, 683-705.
34. Nebert, D.W., Zhang, G., and Vesell, E.S. (2008). From human genetics and genomics to pharmacogenetics and pharma-cogenomics: past lessons, future directions. Drug Metab Rev 40, 187-224.
35. Ordovas, J.M., and Mooser, V. (2004). Nutrigenomics and nu-trigenetics. Curr Opin Lipidology 15, 101-108.
36. Ozdemir, V., and Godard, B. (2007). Evidence-based management of nutrigenomics expectations and ELSIs. Pharmacoge-nomics 8, 1051-1062.
37. Ozdemir, V., Kalow, W., Tang, B.K., Paterson, A.D., Walker, S.E., Endrenyi, L., et al. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenet Genomics 10, 373-388.
38. Ozdemir, V., Kalow, W., Tothfalusi, L., Bertilsson, L., Endrenyi, L., and Graham, J.E. (2005). Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics Personal Med 3, 53-71.
39. Ozdemir, V., Suarez-Kurtz, G., Stenne, R., Somogyi, A.A., Someya, T., Kayaalp, S.O., et al. (2009). Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS 13, 43-61.
40. Saltelli, A., and Funtowicz, S. (2004). The precautionary principle: implications for risk management strategies. Int J Occup Med Environ Health 17, 47-57.
41. Snyder, L.H. (1931). Inherited taste deficiency. Science 74, 151-152.
42. Tepper, B.J. (2008). Nutritional implications of genetic taste variation: the role of PROP sensitivity and other taste phenotypes. Annu Rev Nutr 28, 14.1-14.22.
43. Teucher, B., Skinner, J., Skidmore, P.M., Cassidy, A., Fair weather-Tait, S.J., Hooper, L., et al. (2007). Dietary patterns and heritability of food choice in a UK female twin cohort. Twin Res Hum Genet 10, 734-748.
44. UNESCO. (2000). World Conference on Science. "Science for the twenty-first century: a new commitment" (Declaration on Science and the Use of Scientific Knowledge). Sci Technol Soc 5, 81-92.
45. Vogel, F. (1959). Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk, 12, 52-125.
46. Vogel, F., Buselmaier, W., Reichert, W., Kellermann, G., and Berg, P., eds. (1978). Human Genetic Variation in Response to Medical and Environmental Agents: Pharmacogenetics and Ecoge-netics. International Titisee Conference, Titisee, 13-15 Oct 1977. Hum Genet 1(Suppl.) 1-192.
47. Williams, R.J. (1956). Biochemical individuality. (John Wiley & Sons, New York).